12/2
08:04 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at HC Wainwright from $80.00 to $85.00. They now have a "buy" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at HC Wainwright from $80.00 to $85.00. They now have a "buy" rating on the stock.
12/2
07:30 am
arwr
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Low
Report
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
12/1
04:00 pm
arwr
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
Low
Report
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
12/1
11:42 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Bank of America Corporation from $42.00 to $62.00. They now have a "buy" rating on the stock.
Low
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Bank of America Corporation from $42.00 to $62.00. They now have a "buy" rating on the stock.
12/1
08:09 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
11/27
07:46 pm
arwr
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript [Seeking Alpha]
Medium
Report
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript [Seeking Alpha]
11/27
11:01 am
arwr
Arrowhead: Gains Make Mockery Of My Sell Call - But Jury May Still Be Out (Rating Upgrade) [Seeking Alpha]
Medium
Report
Arrowhead: Gains Make Mockery Of My Sell Call - But Jury May Still Be Out (Rating Upgrade) [Seeking Alpha]
11/27
01:29 am
arwr
Arrowhead Pharmaceuticals (ARWR) Is Up 48.1% After First FDA Approval for siRNA Rare Disease Therapy [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals (ARWR) Is Up 48.1% After First FDA Approval for siRNA Rare Disease Therapy [Yahoo! Finance]
11/26
12:07 pm
arwr
Stocks making the biggest moves midday: Dell, Arrowhead Pharmaceuticals, Urban Outfitters & more [CNBC]
Low
Report
Stocks making the biggest moves midday: Dell, Arrowhead Pharmaceuticals, Urban Outfitters & more [CNBC]
11/26
10:19 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Morgan Stanley from $45.00 to $48.00. They now have an "equal weight" rating on the stock.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Morgan Stanley from $45.00 to $48.00. They now have an "equal weight" rating on the stock.
11/26
12:30 am
arwr
Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ... [Yahoo! Finance]
High
Report
Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ... [Yahoo! Finance]
11/25
04:26 pm
arwr
Arrowhead Pharmaceuticals GAAP EPS of -$0.01 in-line, revenue of $829.45M beats by $72.01M [Seeking Alpha]
High
Report
Arrowhead Pharmaceuticals GAAP EPS of -$0.01 in-line, revenue of $829.45M beats by $72.01M [Seeking Alpha]
11/25
04:00 pm
arwr
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
High
Report
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
11/24
07:30 am
arwr
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
Medium
Report
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
11/21
04:12 am
arwr
A Look at Arrowhead Pharmaceuticals's Valuation Following FDA Approval of First siRNA Therapy for Rare Disease [Yahoo! Finance]
Medium
Report
A Look at Arrowhead Pharmaceuticals's Valuation Following FDA Approval of First siRNA Therapy for Rare Disease [Yahoo! Finance]
11/20
05:25 pm
arwr
Analyzing Arrowhead Pharmaceuticals After Doubling in Price With RNA Therapy Breakthroughs [Yahoo! Finance]
Medium
Report
Analyzing Arrowhead Pharmaceuticals After Doubling in Price With RNA Therapy Breakthroughs [Yahoo! Finance]
11/20
08:07 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $27.00 to $48.00. They now have a "neutral" rating on the stock.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $27.00 to $48.00. They now have a "neutral" rating on the stock.
11/19
11:02 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Royal Bank Of Canada from $45.00 to $52.00. They now have an "outperform" rating on the stock.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Royal Bank Of Canada from $45.00 to $52.00. They now have an "outperform" rating on the stock.
11/19
08:47 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
11/19
08:07 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Piper Sandler from $45.00 to $70.00. They now have an "overweight" rating on the stock.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Piper Sandler from $45.00 to $70.00. They now have an "overweight" rating on the stock.
11/19
03:52 am
arwr
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript [Seeking Alpha]
Medium
Report
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses FDA Approval and Commercial Launch Plans for REDEMPLO in Familial Chylomicronemia Syndrome Transcript [Seeking Alpha]
11/19
12:08 am
arwr
Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway [Seeking Alpha]
Medium
Report
Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway [Seeking Alpha]
11/18
07:06 pm
arwr
RNAi biotech Arrowhead wins first FDA approval [Yahoo! Finance]
Medium
Report
RNAi biotech Arrowhead wins first FDA approval [Yahoo! Finance]
11/18
12:46 pm
arwr
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) [Yahoo! Finance]
Medium
Report
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) [Yahoo! Finance]
11/18
11:52 am
arwr
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Low
Report
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)